Arctic Bioscience reported Q2 2025 revenue of NOK 18,695,578 with a gross profit of NOK 7,216,478, yielding a gross margin of 38.6%. The quarter delivered a meaningful YoY revenue uplift of 37.5%, but the operating and net framework remained deeply loss-making, with EBITDA of NOK -14,736,114 and net income of NOK -18,944,966. Management commentary is not provided in the transcript snapshot; however, the reported cost structure highlights a heavily front-loaded SG&A (NOK 10,706,074) and substantial other expenses (NOK 11,556,502) that drive a large operating loss (NOK -16,177,540) and negative earnings per share of NOK -0.70. The business remains in an early-stage commercial and clinical phase, guided by development milestones rather than sustainable cash generation from product sales in the near term.
From a balance sheet and liquidity perspective, the company shows limited short-term liquidity with a current ratio of 0.826, quick ratio of 0.339, and cash ratio of 0.0373, underscoring a fragile near-term runway absent external funding or milestone-based inflows. Debt levels are modest (debt ratio 0.190; long-term debt to capitalization 0.0581), suggesting low leverage, but liquidity constraints and persistent cash burn cast a clear focus on financing and capital allocation. The revenue expansion is driven by existing nutraceutical components (bulk ingredient sales) and a development program focused on HRO350, a novel oral psoriasis candidate. Investors should monitor clinical milestones for HRO350, potential strategic partnerships, and any financing announcements, as these catalysts would be pivotal to repositioning profitability and balance-sheet resilience.